menu
    • menu

    Company profile for Anbogen Therapeutics

    NEW Drugs in Dev: 2
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Anbogen Therapeutics (ABT) is a clinical stage biopharmaceutical company founded in 2019, focusing on discovering and developing precision medicine in oncology.Anbogen Therapeutics is a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients. Founded by a group of exceptional scientists from National Health Research Institute, the most prestigious medical research in...
    Anbogen Therapeutics (ABT) is a clinical stage biopharmaceutical company founded in 2019, focusing on discovering and developing precision medicine in oncology.Anbogen Therapeutics is a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients. Founded by a group of exceptional scientists from National Health Research Institute, the most prestigious medical research institute in Taiwan, Anbogen Therapeutics is devoted to bring gap between research and clinical development, and dedicated to creating breakthrough science that meaningfully changes life of patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Anbogen TherapeuticsTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    No. 99, Lane 130, Sec. 1, Research Institute Road, Nangang District, Taipei Ci...
    Telephone
    Telephone
    02-27421839#815
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://anbogen.com/en/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA clears Anbogen to start Phase 1/2 trial of ABT-301
    FDA clears Anbogen to start Phase 1/2 trial of ABT-301

    04 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/anbogen-receives-fda-clearance-to-initiate-phase-12-trial-of-abt-301-triplet-therapy-for-advanced-colorectal-cancer-302520490.html

    PR NEWSWIRE
    04 Aug 2025
    Share Share
    Anbogen Inks Deal With BeiGene For Colorectal Cancer Therapy
    Anbogen Inks Deal With BeiGene For Colorectal Cancer Therapy

    27 Sep 2024

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/24959/taiwans-anbogen-inks-deal-with-beigene-to-evaluate-combination-therapy-in-colorectal-cancer.html

    BIOSPECTRUM ASIA
    27 Sep 2024
    Share Share
    Anbogen Completes A+ Financing For ABT-301 Phase II Trial
    Anbogen Completes A+ Financing For ABT-301 Phase II Trial

    01 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/anbogen-therapeutics-announces-completion-of-a-round-financing-to-advance-abt-301-phase-ii-clinical-trial-302183967.html

    PR NEWSWIRE
    01 Jul 2024
    Share Share
    Anbogen Secures 12.5 Million in Series A Funding
    Anbogen Secures 12.5 Million in Series A Funding

    31 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/anbogen-secures-12-5-million-in-series-a-funding-advancing-precision-oncology-drug-development-302047682.html

    PR NEWSWIRE
    31 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search